| 产品名称： | Candida albicans (Robin) Berkhout |
|---|---|
| 商品货号： | TS148442 |
| Deposited As： | Candida albicans (Robin) Berkhout, anamorph |
| Strain Designations： | X657 NIH B207, R.S. Gordee A26 |
| Application： | assay of A32390A antibiotic A32390A assay of cilofungin LY121019 |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Product Format： | freeze-dried |
| Type Strain： | no |
| Preceptrol®： | no |
| Comments： | highly virulent for laboratory animals |
| Medium： | ATCC® Medium 28: Emmons modification of Sabourauds agar |
| Growth Conditions： | Temperature: 24.0°C |
| Name of Depositor： | Eli Lilly & Co. |
| Chain of Custody： | ATCC < |
| Isolation： | clinical isolate |
| References： | Turner JR, et al. A32390A, a new biologically active metabolite. III. In vitro and in vivo antifungal activity. J. Antibiot. 31: 33-37, 1978. PubMed: 342474 Turner JR, et al. Colonization of the intestinal tract of conventional mice with Candida albicans and treatment with antifungal agents. Antimicrob. Agents Chemother. 9: 787-792, 1976. PubMed: 782356 Debono M, et al. Synthesis and evaluation of LY121019, a member of a series of semisynthetic analogues of the antifungal lipopeptide echinocandin B. Ann. N.Y. Acad. Sci. 544: 152-167, 1988. PubMed: 3063167 Gordee RS, et al. In vitro and in vivo anti-Candida activity and toxicology of LY121019. J. Antibiot. 37: 1054-1065, 1984. PubMed: 6389460 |
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | Candida albicans (Robin) Berkhout |
|---|---|
| 商品货号： | TS148442 |
| Deposited As： | Candida albicans (Robin) Berkhout, anamorph |
| Strain Designations： | X657 NIH B207, R.S. Gordee A26 |
| Application： | assay of A32390A antibiotic A32390A assay of cilofungin LY121019 |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Product Format： | freeze-dried |
| Type Strain： | no |
| Preceptrol®： | no |
| Comments： | highly virulent for laboratory animals |
| Medium： | ATCC® Medium 28: Emmons modification of Sabourauds agar |
| Growth Conditions： | Temperature: 24.0°C |
| Name of Depositor： | Eli Lilly & Co. |
| Chain of Custody： | ATCC < |
| Isolation： | clinical isolate |
| References： | Turner JR, et al. A32390A, a new biologically active metabolite. III. In vitro and in vivo antifungal activity. J. Antibiot. 31: 33-37, 1978. PubMed: 342474 Turner JR, et al. Colonization of the intestinal tract of conventional mice with Candida albicans and treatment with antifungal agents. Antimicrob. Agents Chemother. 9: 787-792, 1976. PubMed: 782356 Debono M, et al. Synthesis and evaluation of LY121019, a member of a series of semisynthetic analogues of the antifungal lipopeptide echinocandin B. Ann. N.Y. Acad. Sci. 544: 152-167, 1988. PubMed: 3063167 Gordee RS, et al. In vitro and in vivo anti-Candida activity and toxicology of LY121019. J. Antibiot. 37: 1054-1065, 1984. PubMed: 6389460 |
